Insider Trading Activity Alkermes Plc (NASDAQ:ALKS) – SVP Sold 10,000 shares of Stock

10

Insider Trading Activity For Alkermes Plc (NASDAQ:ALKS)

Michael J Landine , SVP of Alkermes Plc (NASDAQ:ALKS) reportedly Sold 10,000 shares of the company’s stock at an average price of 57.23 for a total transaction amount of $572,300.00 SEC Form

Insider Trading History For Alkermes Plc (NASDAQ:ALKS)

  • On 1/16/2014 James Frates, CFO, sold 7,000 with an average share price of $47.40 per share and the total transaction amounting to $331,800.00. View SEC Filing
  • On 1/16/2014 Gordon Pugh, COO, sold 30,000 with an average share price of $47.16 per share and the total transaction amounting to $1,414,800.00. View SEC Filing
  • On 1/16/2014 Elliot Ehrich, CMO, sold 14,555 with an average share price of $47.35 per share and the total transaction amounting to $689,179.25. View SEC Filing
  • On 1/21/2014 Elliot Ehrich, CMO, sold 7,718 with an average share price of $48.61 per share and the total transaction amounting to $375,171.98. View SEC Filing
  • On 2/3/2014 Paul Mitchell, Director, sold 1,500 with an average share price of $48.15 per share and the total transaction amounting to $72,225.00. View SEC Filing
  • On 2/18/2014 Elliot Ehrich, CMO, sold 7,718 with an average share price of $52.45 per share and the total transaction amounting to $404,809.10. View SEC Filing
  • On 3/5/2014 James Frates, CFO, sold 7,000 with an average share price of $47.78 per share and the total transaction amounting to $334,460.00. View SEC Filing
  • Analyst Ratings For Alkermes Plc (NASDAQ:ALKS)
    These are 3 Hold Ratings, 7 Buy Ratings .
    The current consensus rating for Alkermes Plc (NASDAQ:ALKS) is Buy (Score: 2.70) with a consensus target price of $64.40 , a potential (11.21% upside)

    Analyst Ratings History For Alkermes Plc (NASDAQ:ALKS)

    • On 1/21/2016 Guggenheim Reiterated Rating Hold with a price target of $57.00 to $35.00
    • On 5/26/2016 Evercore ISI Initiated Coverage of rating Buy with a price target of $59.00
    • On 7/29/2016 Barclays PLC Boost Price Target of rating Overweight with a price target of $65.00 to $66.00
    • On 9/27/2016 Citigroup Inc Boost Price Target of rating Neutral with a price target of $44.00 to $53.00
    • On 10/21/2016 Leerink Swann Boost Price Target of rating Outperform with a price target of $57.00 to $70.00
    • On 3/16/2017 Cantor Fitzgerald Reiterated Rating Neutral with a price target of $51.00

    About Alkermes Plc (NASDAQ:ALKS)
    Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company’s products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company’s product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

    Recent Trading Activity for Alkermes Plc (NASDAQ:ALKS)
    Shares of Alkermes Plc closed the previous trading session at 57.91 down -0.02 -0.03% with 728,642 shares trading hands.

    An ad to help with our costs